Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab

2021 Year in Review - Biosimilars - Biosimilars

A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates.

Clinical studies have demonstrated biosimilarity of the biosimilar trastuzumab-dkst to trastuzumab originator in the metastatic setting. In the real-world setting, a retrospective study compared the pathologic complete response (pCR) rates achieved with neoadjuvant use of trastuzumab-dkst with trastuzumab neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).

The study included patients with HER2-positive EBC treated with neoadjuvant trastuzumab from November 2018 to October 2019 and trastuzumab-dkst from December 2019 to September 2020 in Alberta, Canada. A logistic regression model was applied by trastuzumab product (trastuzumab vs trastuzumab-dkst), age (<40 years vs ≥40 years), preoperative T (T1/2 vs T3/4) and N stage (negative vs positive), grade (I/II vs III), hormone receptor status (estrogen receptor and/or progesterone receptor positive vs estrogen receptor/progesterone receptor negative), HER2 (3+ vs silver in situ hybridization+), chemotherapy (anthracycline containing vs not), and chemotherapy completion (yes vs no).

A total of 136 patients were identified, of which 56% of patients received trastuzumab and 43% received trastuzumab-dkst. Baseline characteristics were mostly comparable between the 2 groups, except a higher proportion of patients in the trastuzumab-dkst group were clinically N-negative (39% vs 14.3%; P = .001). The pCR rates were comparable between trastuzumab-dkst and trastuzumab (35.6% vs 40.3%; P = .598). In the logistic regression model, the odds of a pCR were not different between treatment with trastuzumab-dkst and trastuzumab (odds ratio, 1.1; 95% confidence interval, 0.5-2.4; P = .850). Anthracycline use was associated with a trend for decreased odds of pCR (odds ratio, 0.72; 95% confidence interval, 0.3-1.6; P = .417). Moreover, the estimated cost-savings of trastuzumab-dkst therapy was $22,000 (for a 65-kg patient).

Based on the results of this real-world analysis, the authors concluded that patients with HER2-positive EBC treated with trastuzumab-dkst versus trastuzumab in the neoadjuvant setting achieved similar pCR rates, which were comparable with results obtained in pivotal phase 3 trials.

Source: Yang C, Khwaja R, King K, et al. Trastuzumab-dkst versus trastuzumab: real-world pCR rates in patients with HER2>+ breast cancer treated with neoadjuvant chemotherapy plus trastuzumab from Alberta, Canada. J Clin Oncol. 2021;39(suppl_15):e12569.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: